CVE-2024-41668: The cBioPortal for Cancer Genomics provides visualization, analysis, and download of large-scale cancer genomics data sets. When running a publicly ex...

Description

The cBioPortal for Cancer Genomics provides visualization, analysis, and download of large-scale cancer genomics data sets. When running a publicly exposed proxy endpoint without authentication, cBioPortal could allow someone to perform a Server Side Request Forgery (SSRF) attack. Logged in users could do the same on private instances. A fix has been released in version 6.0.12. As a workaround, one might be able to disable `/proxy` endpoint entirely via, for example, nginx.

Metrics

CVSS 3.1

8.3/10

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:C/C:L/I:L/A:L

EPSS Probability

0.58%

43.3th percentile

Probability of exploitation in the next 30 days. Learn more

Weakness Enumeration

CWE-918

References

Timeline

Published: Jul 23, 2024
Last Modified: Jun 17, 2026
Status: Deferred

Frequently Asked Questions

What is CVE-2024-41668?

The cBioPortal for Cancer Genomics provides visualization, analysis, and download of large-scale cancer genomics data sets. When running a publicly exposed proxy endpoint without authentication, cBioPortal could allow someone to perform a Server Side Request Forgery (SSRF) attack. Logged in users could do the same on private instances. A fix has been released in version 6.0.12. As a workaround, one might be able to disable `/proxy` endpoint entirely via, for example, nginx.

How severe is CVE-2024-41668?

CVE-2024-41668 has a CVSS score of 8.3/10 (HIGH severity). The EPSS model estimates a 0.58% probability of exploitation in the next 30 days.

How do I fix CVE-2024-41668?

Check the vendor references and advisories linked above for patched versions and mitigation guidance. You can also run a Strix scan to test if your systems are affected.